2023
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium
Koops S, Allott K, de Haan L, Chen E, Hui C, Killackey E, Long M, Moncrieff J, Sommer I, Stürup A, Wunderink L, Begemann M, van der A J, Bakker P, Beer F, Begemann M, van Beveren N, Boonstra T, Brand B, Djordjevic M, Franke S, Gangadin S, Guloksuz S, Haan L, van ‘t Hag G, Hamers I, van der Heijden-Hobus I, Hoornaar R, Huizer K, Kikkert M, Koops S, Lokkerbol J, Marcelis M, Oomen P, van Os J, Rosema B, Sommer I, Smit F, Veling W, Voppel A, Albert N, Karlsen M, Nordentoft M, Speyer H, Stürup A, Allott K, Killackey E, O’Donoghue B, Stainton A, Cooper R, Conneely M, Grünwald L, Haynes N, Horowitz M, Mason J, Long M, Moncrieff J, Priebe S, Stansfeld J, Vasiliki G, Chen E, Hui C, Wunderink L, Liu C, Berna F, Foucher J. Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium. Schizophrenia Bulletin 2023, 50: 5-8. PMID: 37625022, PMCID: PMC10754158, DOI: 10.1093/schbul/sbad112.Peer-Reviewed Original Research
2022
Polygenic risk scores for predicting outcomes and treatment response in psychiatry: hope or hype?
Fusar-Poli L, Rutten B, van Os J, Aguglia E, Guloksuz S. Polygenic risk scores for predicting outcomes and treatment response in psychiatry: hope or hype? International Review Of Psychiatry 2022, 34: 663-675. PMID: 36786114, DOI: 10.1080/09540261.2022.2101352.Peer-Reviewed Original ResearchMeSH KeywordsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMental DisordersMultifactorial InheritancePsychiatryRisk FactorsConceptsPolygenic risk scoresTreatment responseRisk scoreMental disordersDetailed clinical characterizationPresent narrative reviewPotential clinical utilityMajor mental disordersIndividual genetic predispositionRisk stratificationPrognostic evaluationClinical characterizationWide association study datasetsClinical utilityGeneral populationGenetic predispositionNarrative reviewSingle nucleotide polymorphismsGeneral psychopathology and its social correlates in the daily lives of youth
Achterhof R, Kirtley O, Schneider M, Hagemann N, Hermans K, Hiekkaranta A, Lecei A, Decoster J, Derom C, De Hert M, Gülöksüz S, Jacobs N, Menne-Lothmann C, Rutten B, Thiery E, van Os J, van Winkel R, Wichers M, Myin-Germeys I. General psychopathology and its social correlates in the daily lives of youth. Journal Of Affective Disorders 2022, 309: 428-436. PMID: 35500686, DOI: 10.1016/j.jad.2022.04.147.Peer-Reviewed Original ResearchInterplay between genetic background and environmental factors in psychiatry: current situation and future prospects.
Rutten B, Guloksuz S, Boks M, van Os J, Luykx J, van Winkel R. Interplay between genetic background and environmental factors in psychiatry: current situation and future prospects. Tijdschrift Voor Psychiatrie 2022, 64: 317-322. PMID: 35735044.Peer-Reviewed Original Research
2021
Immunomodifying and neuroprotective effects of noscapine: Implications for multiple sclerosis, neurodegenerative, and psychiatric disorders
Altinoz M, Guloksuz S, Ozpinar A. Immunomodifying and neuroprotective effects of noscapine: Implications for multiple sclerosis, neurodegenerative, and psychiatric disorders. Chemico-Biological Interactions 2021, 352: 109794. PMID: 34963564, DOI: 10.1016/j.cbi.2021.109794.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyotrophic Lateral SclerosisAnimalsBradykininHistamine AntagonistsHumansImmunomodulating AgentsIon ChannelsMental DisordersMultiple SclerosisNeurodegenerative DiseasesNeuroprotective AgentsNoscapineOligodendrogliaParkinsonian DisordersReceptors, G-Protein-CoupledSignal TransductionStrokeConceptsNeuroprotective effectsMultiple sclerosisInflammatory transcription factor NF-κBIschemic brain damageNeonatal rat pupsPilot clinical studyAmyotrophic lateral sclerosisTranscription factor NF-κBCortical neuronal cellsSignificant therapeutic efficacyFactor NF-κBBitter taste receptorsHistaminergic systemBrain damageRat pupsClinical studiesSK channelsLateral sclerosisParkinson's diseaseAnxiolytic activityPsychiatric disordersChemical injuryNF-κBAnimal modelsPsychiatric diseasesAntipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLOS ONE 2021, 16: e0244944. PMID: 33596211, PMCID: PMC7888647, DOI: 10.1371/journal.pone.0244944.Peer-Reviewed Original ResearchConceptsAntipsychotic-naive patientsBody weight changesBody weight gainWeight gainPsychiatric diagnosisNaive patientsWeight changeAntipsychotic useBodyweight gainAntipsychotic-naive groupMore weight gainDiagnosis of schizophreniaAntipsychotic switchMost antipsychoticsShort followSwitch studyMetabolic disturbancesClinical trialsOutcome measuresAntipsychoticsPatientsBody weightNaive groupSwitch groupDiagnosis
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight lossScience, Psychiatry, and the DSM.
Atbaşoğlu E, Gülöksüz S. Science, Psychiatry, and the DSM. Turkish Journal Of Psychiatry 2013, 24: 202-12. PMID: 24049010, DOI: 10.5080/u7220.Peer-Reviewed Original ResearchMeSH KeywordsDiagnostic and Statistical Manual of Mental DisordersHumansMental DisordersPsychiatryScienceTurkeyConceptsGeneral medical conditionsGood vantage pointContemporary psychiatryBranches of medicineDetailed medical assessmentGeneral medical diagnosisVantage pointPsychiatryMedical conditionsApproach todayDSM disordersMedical assessmentStructural abnormalitiesMental disordersBiopsychosocial approachPsychiatric phenomenaSpecific causesStatistical ManualDiagnostic reliabilityScientific problemsDimensions of moodDisordersScienceMain scientific problemsDisciplines